Yousif Capital Management LLC Purchases New Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

Yousif Capital Management LLC acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 8,824 shares of the biopharmaceutical company's stock, valued at approximately $275,000.

Other institutional investors have also bought and sold shares of the company. Adage Capital Partners GP L.L.C. increased its stake in Royalty Pharma by 42.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock valued at $432,862,000 after buying an additional 5,069,127 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Royalty Pharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock valued at $186,846,000 after acquiring an additional 46,765 shares in the last quarter. Norges Bank acquired a new position in shares of Royalty Pharma during the fourth quarter valued at approximately $124,498,000. Two Sigma Advisers LP raised its holdings in Royalty Pharma by 21.1% during the fourth quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock worth $93,703,000 after purchasing an additional 640,000 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Royalty Pharma by 12.8% during the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock worth $84,959,000 after purchasing an additional 376,619 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Price Performance

NASDAQ:RPRX traded down $0.23 during trading hours on Wednesday, reaching $35.91. 2,525,386 shares of the company's stock were exchanged, compared to its average volume of 3,667,077. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $20.19 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 1.81 and a beta of 0.48. Royalty Pharma PLC has a 12 month low of $24.05 and a 12 month high of $36.32. The business's 50-day simple moving average is $33.27 and its two-hundred day simple moving average is $31.38.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.07. The business had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. Sell-side analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a $0.22 dividend. The ex-dividend date was Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.45%. Royalty Pharma's dividend payout ratio (DPR) is 47.57%.

Analyst Ratings Changes

A number of brokerages have issued reports on RPRX. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Wall Street Zen raised Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Morgan Stanley started coverage on Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $47.33.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.